CA-QUANTA-CLOUD-TECH
29.6.2021 18:02:10 CEST | Business Wire | Press release
Quanta Cloud Technology (QCT), a global data center solution provider, announced OmniRAN, its virtualized radio access network (vRAN) solution developed with its long-term partners, Intel and Radisys. The solution uses Intel FlexRAN , a cloud-enabled wireless access virtual network functions reference implementation, and Radisys Connect 5G RAN software, a disaggregated RAN architecture for promoting 4G, 5G and IoT to build a cloud-native vRAN based on 3rd Gen Intel Xeon Scalable Processors running on QCT EGX63IS-1U servers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210629005459/en/
To deliver low-latency and power-efficient services with the flexibility to increase or decrease capacity based on the volume of real-time traffic demands, Intel’s vRAN dedicated accelerator, ACC100, for forward error correction (FEC) acceleration is also an essential part of the integrated solution. Intel’s 5G optimized network adapter, codenamed Westport Channel, is also implemented for accurate time synchronization without the added complexity or expenses that come with specialty timing hardware. This validated combination on QCT EGX63IS-1U extends distributed unit (DU) capabilities to support multi-cell and multi-RRU 5G scenarios, delivering reliable performance for various network workloads.
As operators are increasingly looking for ways to accelerate their 5G network deployments by leveraging disaggregated and open reference architecture solutions, OpenRAN-based OmniRAN is designed to minimize the challenges of infrastructure deployment and maximize value of ownership. OmniRAN has already been successfully deployed in smart manufacturing use cases such as safety AI for environment control, high-resolution streaming for quality control, AR goggles for maintenance and repair, and autonomous guided vehicles (AGV) for equipment transport. Not only does OmniRAN provide improved performance such as wider coverage and enhanced mobility, but also offer centralized management as well as greater scalability and deployment flexibility while achieving significant cost savings.
“QCT works closely with its partners to ensure that customers can always stay ahead of the game,” said Mike Yang, President of QCT. “Incorporating the newest technologies and features from Intel and Radisys, QCT’s latest vRAN solution improves capital and operational efficiencies by optimizing resource utilization and making software-defined management and orchestration possible.”
“Open 5G networks are the next step for customers across many sectors, and Radisys, along with our partners, is providing open, disaggregated and virtualized RAN solutions to meet varying business demands,” said Munish Chhabra, head of Mobility Software and Services Business, Radisys. “We are excited to power the QCT vRAN solution through our market first Release 16 Radisys 5G software stack. The integrated solution enables mobile operators and enterprises to benefit from reduced costs, improved network efficiencies, and faster time-to-market of new services that open APIs and open architectures provide.”
“This demonstration from Intel, QCT, and Radisys is important for accelerating broader adoption of 5G,” said Cristina Rodriguez, Intel VP and GM of Data Center Group, Wireless Access Network Division. “By defining the FlexRAN reference architecture and collaborating with our Intel Network Builders, Intel is expanding its growing portfolio of technology and ecosystem to ensure interoperability, enhanced performance, and reduced overhead for service providers all over the globe.”
For more information visit https://go.qct.io/telco/ .
About Quanta Cloud Technology (QCT)
Quanta Cloud Technology (QCT) is a global data center solution provider. We combine the efficiency of hyperscale hardware with infrastructure software from a diversity of industry leaders to solve next-generation data center challenges. QCT serves cloud service providers, telecoms and enterprises running public, hybrid and private clouds.
Intel, the Intel logo and other Intel marks are trademarks of Intel Corporation or its subsidiaries. Other names and brands may be claimed as the property of others.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210629005459/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
First Plus Expands Relationship with SS&C to Support Cross-Border Operations in APAC3.8.2026 03:00:00 CEST | Press release
SS&C Technologies Holdings, Inc. (Nasdaq: SSNC) today announced that First Plus Asset Management (FPAM), a multi-asset investment management firm, has selected SS&C to provide cross-border operations support across Asia. SS&C will service First Plus across the full investment lifecycle, delivering a scalable, integrated solution supporting transfer agency, order management and execution and investment accounting. FPAM will utilize SS&C to service its growing cross-border operating model and support around $200 million in assets under management*. “As First Plus has expanded, managing our operations has become increasingly complex,” said Jeb Li, Co-Founder and CEO at First Plus. “SS&C’s global footprint and integrated offerings enable us to easily optimize our workflows, so we can focus on scaling quickly and securely while continuing to deliver risk-adjusted returns and best-in-class client service.” The engagement highlights the breadth and scalability of SS&C’s global service model.
Europe’s Largest Celebration of Irish Culture Arrives in Belfast2.8.2026 10:01:00 CEST | Press release
Fleadh Cheoil na hÉireann arrives in Belfast today (2 August), bringing eight days of traditional music, culture and celebration to the city, with organisers expecting up to 800,000 visitors over the course of the festival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260729147569/en/ Belfast Fleadh - Maddens Bar accordian, guitar and fiddle player (Chris Heaney) One of Europe’s largest cultural events, Fleadh Cheoil na hÉireann is taking place in Belfast for the first time, transforming the city into a vibrant stage for Irish music, dance, language and culture. More than 200 events and 180 traditional music competitions are taking place across venues, streets and neighbourhoods throughout the week-long celebration. The landmark festival showcases the very best of Irish culture, with a packed programme of All-Ireland competitions, concerts, community events and performances from both established and emerging artists. As Ir
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
